Sangamo selloff attracts buyers

By
A A A

Sangamo Biosciences fell hard today, and some traders are stepping in.

optionMONSTER's Heat Seeker monitoring system detected unusual call buying in the drug developer, which is down 25 percent after announcing poor Phase 2 trial results for its SB-509 diabetes treatment. The November 3 contracts were the busiest strike, with more than 1,000 contracts purchased for $0.90 and $0.95. Volume was 100 times previous open interest.

About 600 November 6 calls were also purchased for $0.15, but activity was within the earlier positioning.

SGMO is trading at a $3.28 after hitting a new 52-week low of $3.13 earlier in the session. It attempted to rally on Sept. 19 after announcing one of its compounds offered a "functional cure" for HIV/AIDS, but the bears stepped in and it's been falling ever since.

The company focuses on using molecular genetics to cure disease, and all of its potential products are in early stages of development.

Overall option volume in SGMO is quadruple the daily average so far today, with calls outnumbering puts by 7 to 1.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Copyright © 2010 OptionMonster® Holdings, Inc. All Rights Reserved.


This article appears in: Investing , Options

Referenced Stocks: SGMO

optionMONSTER

optionMONSTER

More from optionMONSTER:

Related Videos

Russell’s One Good Reason
Russell’s One Good Reason           
Tammy’s One Good Reason
Tammy’s One Good Reason             
Lisa’s One Good Reason
Lisa’s One Good Reason              

Stocks

Referenced

Most Active by Volume

87,324,760
  • $7.31 ▲ 22.04%
79,329,227
  • $17.16 ▲ 0.76%
74,153,988
  • $8.87 ▼ 5.84%
49,177,672
  • $34.01 ▲ 4.39%
44,197,901
  • $101.40 ▲ 1.38%
43,197,735
  • $11.70 ▲ 3.36%
42,712,021
  • $74.99 ▲ 1.19%
42,423,171
  • $108 ▲ 0.95%
As of 10/31/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com